Closed-loop Control of Penicillin Delivery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-05

Study Completion Date

2024-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is an in-house feasibility study of penicillin biosensor technology linked with closed-loop control for the automated delivery of penicillin antibiotics.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Minimally Invasive Sensing of Beta-lactam Antibiotics

NCT03847610

Healthy Volunteers

COMPLETED PHASE1

Establishing Immunogenicity and Safety of Needle-free Intradermal Delivery of mRNA COVID-19 Vaccine

NCT05315362

Vaccination; Infection COVID-19

UNKNOWN PHASE2

ElastoMeric Infusion Pumps for Hospital AntibioTICs

NCT05150015

Infection, Bacterial

COMPLETED NA

A Study to Test the Tolerability of an Investigational Electroporation Device in Healthy Adults (V930-001)

NCT00721461

Healthy

COMPLETED PHASE1

A Device Study in Healthy Participants

NCT04848402

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Outline of the study:

This study will take place at the Imperial Clinical Research Facility (ICRF). Twenty healthy volunteers will be recruited to take part in three visits to the ICRF. These will each last 8-12 hours. During these visits participants will receive penicillin via infusion following:

(i) Routine (intermittent or continuous) dosing protocols. (ii) Intermittent dosing directed by a closed-loop control system. (iii) Continuous dosing directed by a closed-loop control system. Participants will have up to 15 blood samples and tissue microdialysis performed. A biosensor will also be used to provide real-time antibiotic concentration data. This will be used to drive the closed-loop control system. Outcome measures will be PK-PD target attainment between visits. This target will be 50% time \> MIC and 100% time \> MIC.

Participant identification:

Healthy volunteers will be recruited from a healthy volunteer database held within Imperial College London and via identification of participants within the College. An initial advertisement e-mail will be sent by the Healthy Volunteer Database Administrator and individuals responding will then followed up by telephone or e-mail and invited to attend a screening visit at the ICRF. They will be sent the participant information leaflet via email in advance of this meeting to give them time to consider the information.

Study methodology:

* Twenty healthy volunteers will be invited to participate in an exploratory study of the biosensor device and closed-loop control systems.
* Allergy status will be confirmed with the participant at each visit.
* Study days will follow the same format. The only deviation will be the method of penicillin delivery (this will either be by routine infusion, closed-loop intermittent infusion, or closed-loop continuous infusion).
* On the night before study visits, participants will be asked to refrain from drinking alcohol. On the study day they will be invited to bring a laptop / tablet device for their entertainment. Alternatively, one will be provided on the study day by the ICRF.
* On arrival at the study center the participant will have a microneedle biosensor sited.
* They will have two cannulae inserted, ideally one in each arm. One of these will be for taking blood during the study. The other will be for penicillin delivery.
* They will also have a microdialysis fibre inserted in the same arm as the microneedle array.
* A baseline blood sample will be taken (full blood count, renal function, liver function, and C-reactive protein) on each visit.
* The microneedle biosensor will be sited peripherally (on the non-dominant arm). These sensors are connected to potentiostat devices that record data, which can then be downloaded onto a computer for analysis.
* The study will then commence at time = 0 when the first infusion of penicillin will be given.
* In total, the study will run for 3 benzylpenicillin dosing intervals (8-12 hours). For intermittent, routine care benzylpenicillin doses will be given at time = 0, 4, and 8 hours. During closed-loop control visits the controller will be allowed to determine the dosing interval / period. The controller will be limited to deliver a MAXIMUM dose equivalent to 2.4g every 4-hours.
* During the study interval the participant will undergo rich blood and microdialysis drug concentration sampling. For blood sampling, up to 15 beta-lactam drug levels will be taken during the study visit period. Each blood test will involve the collection of 5mLs of blood (1 teaspoon). Microdialysis will be performed continuously for the study period. The collection vial will be changed every 15-30 minutes during the study period.
* In addition, a blood spot will be used from the blood samples taken as part of the PK sampling to test point-of-care penicillin sensors at the time-points described below.
* A visual analogue scale will be completed by the participant every hour to evaluate their level of discomfort due to the microneedle sensor device. The device and site will also be checked by researchers every hour.
* Time points for the blood sampling are planned to initially be taken at pre, 6, 10, 15, 30, 60, 120, 180, 240, 246, 250, 300, 480, 486, 600 minutes. However, following initial PK analysis a D-optimal design will be employed using Pmetrics and BestDose pharmacokinetic software to determine the optimal time points for blood PK analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Routine intermittent slow bolus

The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV 1200mg administered every 4 hours.

Group Type EXPERIMENTAL

Microneedle array

Intervention Type DEVICE

The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.

Penicillin G_1200mg

Intervention Type DRUG

Benzylpenicillin IV 1200mg administered every 4 hours.

Closed-loop control of intermittent slow bolus

The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.

Group Type EXPERIMENTAL

Microneedle array and closed-loop control of penicillin delivery

Intervention Type DEVICE

The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Microneedle data will be used to titrate benzylpenicillin dosage according to PK-PD target.

Penicillin G_2400mg

Intervention Type DRUG

Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.

Closed-loop control of continuous infusion

The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.

Group Type EXPERIMENTAL

Microneedle array and closed-loop control of penicillin delivery

Intervention Type DEVICE

The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Microneedle data will be used to titrate benzylpenicillin dosage according to PK-PD target.

Penicillin G_600mg/hr

Intervention Type DRUG

Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Microneedle array

The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.

Intervention Type DEVICE

Microneedle array and closed-loop control of penicillin delivery

The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Microneedle data will be used to titrate benzylpenicillin dosage according to PK-PD target.

Intervention Type DEVICE

Penicillin G_1200mg

Benzylpenicillin IV 1200mg administered every 4 hours.

Intervention Type DRUG

Penicillin G_2400mg

Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.

Intervention Type DRUG

Penicillin G_600mg/hr

Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Benzylpenicillin Benzylpenicillin Benzylpenicillin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult \>18 years old.
* Healthy adults, with no evidence of infection.
* Previously received penicillin with no adverse effects.

Exclusion Criteria

* \< 18 years old.
* High risk of skin and soft tissue infection or local skin and soft tissue infection near sensor site.
* Hypersensitivity to adhesive strips or active dermatitis.
* Penicillin hypersensitivity or previous adverse event whilst receiving penicillin.
* Anaemia on screening bloods (defined as haemoglobin \<13 g/dL in males and \<12 g/dL in females).
* Renal impairment on screening bloods (defined as a Cockcroft-Gault creatinine clearance \<60mL/min).
* Liver impairment on screening bloods (defined as ALT, ALP or bilirubin 3x ULN).
* Implantable electronic device in-situ if wearing a microneedle array device.
* Pregnant.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes